241 related articles for article (PubMed ID: 21659759)
21. Linagliptin blocks renal damage in type 1 diabetic rats by suppressing advanced glycation end products-receptor axis.
Nakashima S; Matsui T; Takeuchi M; Yamagishi SI
Horm Metab Res; 2014 Sep; 46(10):717-21. PubMed ID: 24710699
[TBL] [Abstract][Full Text] [Related]
22. New potential agents in treating diabetic kidney disease: the fourth act.
Williams ME
Drugs; 2006; 66(18):2287-98. PubMed ID: 17181372
[TBL] [Abstract][Full Text] [Related]
23. Role of advanced glycation end products in diabetic nephropathy.
Forbes JM; Cooper ME; Oldfield MD; Thomas MC
J Am Soc Nephrol; 2003 Aug; 14(8 Suppl 3):S254-8. PubMed ID: 12874442
[TBL] [Abstract][Full Text] [Related]
24. Sirt1 resists advanced glycation end products-induced expressions of fibronectin and TGF-β1 by activating the Nrf2/ARE pathway in glomerular mesangial cells.
Huang K; Huang J; Xie X; Wang S; Chen C; Shen X; Liu P; Huang H
Free Radic Biol Med; 2013 Dec; 65():528-540. PubMed ID: 23891678
[TBL] [Abstract][Full Text] [Related]
25. Evolving concepts in advanced glycation, diabetic nephropathy, and diabetic vascular disease.
Jerums G; Panagiotopoulos S; Forbes J; Osicka T; Cooper M
Arch Biochem Biophys; 2003 Nov; 419(1):55-62. PubMed ID: 14568009
[TBL] [Abstract][Full Text] [Related]
26. Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model.
Nangaku M; Miyata T; Sada T; Mizuno M; Inagi R; Ueda Y; Ishikawa N; Yuzawa H; Koike H; van Ypersele de Strihou C; Kurokawa K
J Am Soc Nephrol; 2003 May; 14(5):1212-22. PubMed ID: 12707391
[TBL] [Abstract][Full Text] [Related]
27. Clinical studies of advanced glycation end product inhibitors and diabetic kidney disease.
Williams ME
Curr Diab Rep; 2004 Dec; 4(6):441-6. PubMed ID: 15539009
[TBL] [Abstract][Full Text] [Related]
28. Advanced glycation end products and diabetic nephropathy: a comparative study using diabetic and normal rats with methylglyoxal-induced glycation.
Rodrigues L; Matafome P; Crisóstomo J; Santos-Silva D; Sena C; Pereira P; Seiça R
J Physiol Biochem; 2014 Mar; 70(1):173-84. PubMed ID: 24078283
[TBL] [Abstract][Full Text] [Related]
29. The importance of diabetic nephropathy in current nephrological practice.
Locatelli F; Canaud B; Eckardt KU; Stenvinkel P; Wanner C; Zoccali C
Nephrol Dial Transplant; 2003 Sep; 18(9):1716-25. PubMed ID: 12937216
[TBL] [Abstract][Full Text] [Related]
30. Osteomeles schwerinae extracts inhibits the binding to receptors of advanced glycation end products and TGF-β1 expression in mesangial cells under diabetic conditions.
Kim YS; Jung DH; Lee IS; Pyun BJ; Kim JS
Phytomedicine; 2016 Apr; 23(4):388-97. PubMed ID: 27002409
[TBL] [Abstract][Full Text] [Related]
31. [Extract of Ginkgo biloba and alpha-lipoic acid attenuate advanced glycation end products accumulation and RAGE expression in diabetic nephropathy rats].
Li XZ; Yan HD; Wang J
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2011 Apr; 31(4):525-31. PubMed ID: 21608227
[TBL] [Abstract][Full Text] [Related]
32. Disparate effects on renal and oxidative parameters following RAGE deletion, AGE accumulation inhibition, or dietary AGE control in experimental diabetic nephropathy.
Tan AL; Sourris KC; Harcourt BE; Thallas-Bonke V; Penfold S; Andrikopoulos S; Thomas MC; O'Brien RC; Bierhaus A; Cooper ME; Forbes JM; Coughlan MT
Am J Physiol Renal Physiol; 2010 Mar; 298(3):F763-70. PubMed ID: 20015941
[TBL] [Abstract][Full Text] [Related]
33. Advanced glycation end products mediated cellular and molecular events in the pathology of diabetic nephropathy.
Kumar Pasupulati A; Chitra PS; Reddy GB
Biomol Concepts; 2016 Dec; 7(5-6):293-309. PubMed ID: 27816946
[TBL] [Abstract][Full Text] [Related]
34. Lycopene powers the inhibition of glycation-induced diabetic nephropathy: a novel approach to halt the AGE-RAGE axis menace.
Tabrez S; Al-Shali KZ; Ahmad S
Biofactors; 2015; 41(5):372-81. PubMed ID: 26453295
[TBL] [Abstract][Full Text] [Related]
35. Diabetic nephropathy and advanced glycation end products.
Menè P; Festuccia F; Polci R; Pugliese F; Cinotti GA
Contrib Nephrol; 2001; (131):22-32. PubMed ID: 11125560
[No Abstract] [Full Text] [Related]
36. Expression of receptors for advanced glycation end-products in occlusive vascular and renal disease.
Bierhaus A; Ritz E; Nawroth PP
Nephrol Dial Transplant; 1996; 11 Suppl 5():87-90. PubMed ID: 9044315
[TBL] [Abstract][Full Text] [Related]
37. Roles of advanced glycation end-products in the progression of diabetic nephropathy.
Makino H; Shikata K; Kushiro M; Hironaka K; Yamasaki Y; Sugimoto H; Ota Z; Araki N; Horiuchi S
Nephrol Dial Transplant; 1996; 11 Suppl 5():76-80. PubMed ID: 9044313
[TBL] [Abstract][Full Text] [Related]
38. Advanced glycation: implications in tissue damage and disease.
Gasser A; Forbes JM
Protein Pept Lett; 2008; 15(4):385-91. PubMed ID: 18473952
[TBL] [Abstract][Full Text] [Related]
39. Effect of diabetes and aminoguanidine therapy on renal advanced glycation end-product binding.
Youssef S; Nguyen DT; Soulis T; Panagiotopoulos S; Jerums G; Cooper ME
Kidney Int; 1999 Mar; 55(3):907-16. PubMed ID: 10027927
[TBL] [Abstract][Full Text] [Related]
40. Immunohistochemical detection of advanced glycosylation end products within the vascular lesions and glomeruli in diabetic nephropathy.
Nishino T; Horii Y; Shiiki H; Yamamoto H; Makita Z; Bucala R; Dohi K
Hum Pathol; 1995 Mar; 26(3):308-13. PubMed ID: 7890283
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
